ImmunityBio Gets Good Trial News and an FDA Smackdown in the Same Month. Now What?
NEW YORK, April 10 —
ImmunityBio's Anktiva bladder cancer trial cleared a key statistical hurdle, but an FDA warning letter just wiped $2bn off the stock.
- Q1 2026 net product revenue hit $44.2mn, up 168% YoY and 15% QoQ from $38.3mn in Q4 2025
- Stock at $7.34 with a negative 367x forward P/E. BTIG holds a Buy rating with a $13 price target, nearly double current levels
- Supplemental BLA submission for BCG-naive NMIBC on track for 2026. IDMC confirmed trial is adequately powered at N=366
What Actually Happened
Two things, and they cut in opposite directions. First, the good news: the Independent Data Monitoring Committee reviewed interim complete response data on 183 evaluable patients in the QUILT-2.005 trial comparing Anktiva plus BCG versus BCG alone in BCG-naive bladder cancer patients. The IDMC confirmed the study has enough statistical power to detect pre-specified differences. No additional enrollment needed. The supplemental BLA is on track for 2026, which would expand Anktiva's label beyond its current BCG-unresponsive approval into the much larger BCG-naive population.
Then the bad news. On March 13, the FDA's Office of Prescription Drug Promotion sent a warning letter calling ImmunityBio's promotional materials "false or misleading." The problem: a podcast featuring CEO Patrick Soon-Shiong claimed Anktiva "can actually treat all cancers." The FDA said the materials "grossly misrepresent the benefits of Anktiva," a drug approved for one specific type of bladder cancer. The stock dropped 21% on March 24 when the letter became public. Securities class action lawsuits followed within days.
The Catch
The bull case says this is a promotion compliance issue, not a product safety issue. BTIG maintained its Buy rating and $13 target, calling it something that "can likely be resolved" based on historical precedent. Piper Sandler has an Overweight rating and $12 target, projecting $195mn in 2026 Anktiva revenue. The company had $381mn in cash at quarter end, bolstered by $75mn in non-dilutive funding from Oberland.
The bear case is simpler: the CEO went on a podcast and told cancer patients his drug treats all cancers. That's not a paperwork mistake. That's the kind of thing that invites prolonged FDA scrutiny over future promotional activities. With levered free cash flow still at negative $213mn trailing twelve months, ImmunityBio needs every quarter of clean commercial execution it can get. A company burning $200mn+ a year can't afford distractions from its own CEO.
Bottom Line
The trial data is genuinely encouraging. BCG-naive NMIBC is a bigger market than BCG-unresponsive, and clearing the statistical power check means the supplemental filing stays on schedule. But the FDA warning introduces a variable that has nothing to do with science and everything to do with corporate discipline. The number to watch is the FDA's response timeline and whether the warning escalates beyond a letter. If it stays at the promotion compliance level, the $7.34 stock looks interesting against $13 analyst targets. If it doesn't, the lawsuits become more than ambulance-chasing.
For a deeper look at ImmunityBio's financials and valuation, generate a free Basis Report on IBRX.
Basis Report does not hold positions in securities discussed. This is not investment advice.